92.07
-1.18 (-1.27%)
| Previous Close | 93.25 |
| Open | 92.66 |
| Volume | 374,301 |
| Avg. Volume (3M) | 1,000,868 |
| Market Cap | 6,401,332,224 |
| Price / Earnings (TTM) | 15.29 |
| Price / Earnings (Forward) | 12.27 |
| Price / Sales | 4.49 |
| Price / Book | 5.58 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | 28.57% |
| Operating Margin (TTM) | 35.31% |
| Diluted EPS (TTM) | 6.02 |
| Quarterly Revenue Growth (YOY) | 18.40% |
| Quarterly Earnings Growth (YOY) | -0.70% |
| Total Debt/Equity (MRQ) | 52.67% |
| Current Ratio (MRQ) | 1.65 |
| Operating Cash Flow (TTM) | 499.31 M |
| Levered Free Cash Flow (TTM) | 246.27 M |
| Return on Assets (TTM) | 17.00% |
| Return on Equity (TTM) | 45.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Lantheus Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 3.0 |
| Average | 1.75 |
|
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 2.50% |
| % Held by Institutions | 106.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 143.00 (Goldman Sachs, 55.32%) | Buy |
| Median | 120.00 (30.34%) | |
| Low | 112.00 (JMP Securities, 21.65%) | Buy |
| Average | 125.00 (35.77%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 90.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 14 Jan 2025 | 112.00 (21.65%) | Buy | 92.62 |
| 07 Nov 2024 | 112.00 (21.65%) | Buy | 88.32 | |
| Goldman Sachs | 18 Dec 2024 | 143.00 (55.32%) | Buy | 91.15 |
| Truist Securities | 08 Nov 2024 | 120.00 (30.34%) | Buy | 87.50 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2025 | Announcement | Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market |
| 20 Nov 2024 | Announcement | Lantheus Announces Share Repurchase Program |
| 13 Nov 2024 | Announcement | Lantheus to Present at the Jefferies London Healthcare Conference |
| 11 Nov 2024 | Announcement | Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025 |
| 06 Nov 2024 | Announcement | Lantheus Reports Third Quarter 2024 Financial Results |
| 04 Nov 2024 | Announcement | Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care |
| 23 Oct 2024 | Announcement | Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |